{"id":"NCT02982590","sponsor":"Universiti Sains Malaysia","briefTitle":"Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus","officialTitle":"Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus: A Prospective Randomized Outcome Blinded Study on the Size Reduction or Resolution of Left Ventricular Thrombus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11","primaryCompletion":"2018-11","completion":"2018-11","firstPosted":"2016-12-05","resultsPosted":"2021-07-08","lastUpdate":"2021-07-08"},"enrollment":27,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Left Ventricular Thrombosis"],"interventions":[{"type":"DRUG","name":"Apixaban 5 MG Oral Tablet [ELIQUIS]","otherNames":["ELIQUIS"]},{"type":"DRUG","name":"Warfarin Sodium","otherNames":["Coumadin"]}],"arms":[{"label":"warfarin sodium","type":"ACTIVE_COMPARATOR"},{"label":"apixaban","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare the novel oral anticoagulant apixaban with the standard therapy of warfarin on the size reduction or resolution of left ventricular thrombus over 3 months.","primaryOutcome":{"measure":"Percent Change in Left Ventricular Thrombus (LVT) Size","timeFrame":"3 months","effectByArm":[{"arm":"Warfarin Sodium","deltaMin":-61.45,"sd":43.95},{"arm":"Apixaban","deltaMin":-65.08,"sd":31.34}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Malaysia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":13},"commonTop":["Epistaxis"]}}